Helena A. Yu, MD
The FDA approval of osimertinib (Tagrisso) as a frontline therapy for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR
mutations, specifically exon 19 deletions or exon 21 L858R substitution mutations, has provided physicians with an alternative and more potent treatment for this patient population.
-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.
OncLive: You lectured on sequencing EGFR-targeted therapies in NSCLC. Can you provide an overview?
I spoke about treatments for EGFR
-mutant lung cancer. The first part focused on what data are out there. The real key is the news of osimertinib in the first-line setting. The FLAURA study read out late last year, which showed that osimertinib had a doubling of median PFS compared with what was previously the standard of care. I see osimertinib being the standard of care for first-line treatment.
... to read the full story